公开(公告)号：WO2012058137A3

公开(公告)日：2014-04-10

申请号：PCT/US2011057426

申请日：2011-10-24

申请人： MERCK SHARP & DOHME ,  WANG KEVIN CAILI ,  LI YAN ,  HSIEH MARK ,  WANG XINWEI ,  DONG FENG ,  LUO PEIZHI PETER ,  ZHONG PINGYU

发明人： WANG KEVIN CAILI ,  LI YAN ,  HSIEH MARK ,  WANG XINWEI ,  DONG FENG ,  LUO PEIZHI PETER ,  ZHONG PINGYU

IPC分类号： C12P21/02

CPC分类号： C12N15/1055 ,  C07K16/00 ,  C07K16/005 ,  C07K16/087 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6845

摘要： Disclosed are methods of introducing diversity into antibody molecules substitutions of at least one amino acid sequence in the CDR of the target antibody together with at least one amino acid in the FW region spanning the 3 amino acid adjoining the CRD on each side. The resulting diverse antibodies with variant CDRs and flanking region sequences comprising diverse amino acid sequences Libraries comprising a plurality of these polypeptides are also provided as well as methods of and compositions for generating and using these polypeptides and libraries.

摘要翻译： 公开了将多样性引入到靶抗体的CDR中的至少一个氨基酸序列的取代的多样性的方法以及跨越与每个CRD相邻的3个氨基酸的FW区域中的至少一个氨基酸。 所得到的具有不同CDR的多态抗体和包含不同氨基酸序列的侧翼区序列也提供了包含多个这些多肽的文库以及生成和使用这些多肽和文库的方法和组合物。

公开(公告)号：WO2014003552A1

公开(公告)日：2014-01-03

申请号：PCT/NL2013/050453

申请日：2013-06-26

申请人： APO-T B.V.

发明人： RENES, Johan ,  STEVERINK, Paul ,  WILLEMSEN, Ralph Alexander

IPC分类号： C07K16/08 ,  C07K16/28

CPC分类号： C07K16/18 ,  C07K16/082 ,  C07K16/087 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1045 ,  C07K16/1081 ,  C07K16/1203 ,  C07K16/1214 ,  C07K16/1217 ,  C07K16/1242 ,  C07K16/1271 ,  C07K16/1275 ,  C07K16/1292 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/55

摘要： A first aspect of the invention relates to the field of binding molecules targeted at pathogens. The present invention further relates to proteinaceous binding molecules targeting cells displaying pathogen-associated molecular patterns, in particular targeting cell surface molecules associated with or derived from pathogens, more in particular cell surface proteins displaying peptides from intracellular (pathogen associated) proteins.

摘要翻译： 本发明的第一方面涉及靶向病原体的结合分子的领域。 本发明还涉及靶向显示病原体相关分子模式的细胞的蛋白质结合分子，特别是靶向与病原体相关或衍生自病原体的细胞表面分子，特别是显示来自细胞内（病原体相关）蛋白的肽的细胞表面蛋白。

公开(公告)号：WO2010128053A1

公开(公告)日：2010-11-11

申请号：PCT/EP2010/056047

申请日：2010-05-04

申请人： RIBOVAX BIOTECHNOLOGIES SA ,  ABADIE, Claire ,  COMBETTE, Jean-Marc ,  DELOCHE, Catherine ,  WILLIAMSON, Robert, Anthony

发明人： ABADIE, Claire ,  COMBETTE, Jean-Marc ,  DELOCHE, Catherine ,  WILLIAMSON, Robert, Anthony

IPC分类号： C07K16/08 ,  A61K39/395 ,  A61P27/02

CPC分类号： A61K39/00 ,  A61K2039/505 ,  A61K2039/55511 ,  A61K2121/00 ,  C07K16/00 ,  C07K16/08 ,  C07K16/085 ,  C07K16/087 ,  C07K2317/21

摘要： The present invention relates to the use of a fully human antigen binding fragment of an antibody for the manufacture of a medicament for the treatment or diagnosis of an ocular disease upon topical administration. The invention further relates to a pharmaceutical composition for ocular topical administration for treatment or diagnosis of an ocular disease comprising a fully human binding fragment of an antibody. In particular, the antibody neutralises HSV1 and HSV2.

摘要翻译： 本发明涉及抗体的完全人抗原结合片段在制备用于在局部施用时治疗或诊断眼部疾病的药物中的用途。 本发明还涉及用于眼部局部给药的用于治疗或诊断眼部疾病的药物组合物，其包含抗体的完全人结合片段。 特别地，抗体中和HSV1和HSV2。

公开(公告)号：WO2004050838A3

公开(公告)日：2006-08-03

申请号：PCT/US0337905

申请日：2003-11-28

申请人： DOW CHEMICAL CO ,  DOW AGROSCIENCES LLC ,  BRIGGS KRISTEN ,  GLANCY TODD ,  HEIN MICH B ,  HIATT ANDREW C ,  KARNOUP ANTON S ,  ANDERSON W H KERR ,  PAREDDY DAYAKAR ,  PETOLINO JOSEPH ,  RUBIN-WILSON BETH ,  TAYLOR DOUG ,  ROBERTS JEAN L

发明人： BRIGGS KRISTEN ,  GLANCY TODD ,  HEIN MICH B ,  HIATT ANDREW C ,  KARNOUP ANTON S ,  ANDERSON W H KERR ,  PAREDDY DAYAKAR ,  PETOLINO JOSEPH ,  RUBIN-WILSON BETH ,  TAYLOR DOUG ,  ROBERTS JEAN L

IPC分类号： C12N15/12 ,  A01H1/00 ,  C07K16/00 ,  C07K16/08 ,  C07K16/28 ,  C12N15/82

CPC分类号： C12N15/8258 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/087 ,  C07K16/2839 ,  C07K2317/13 ,  C07K2317/41

摘要： This invention provides for the plant production of immunoglobulins, wherein at least a portion of the glycans attached to the immunoglobulins lack fucose. The invention also provides the constructs; plasmids; vectors; transformed plant cells, transformed plant calli, transformed plant tissues (e.g., leaves, seeds, tubers, etc.) and transformed whole plants used to produce such immunoglobulins; methods of producing the immunoglobulins; the immunoglobulins produced by the disclosed methods; and the use of such immunoglobulins.

摘要翻译： 本发明提供免疫球蛋白的植物生产，其中与免疫球蛋白连接的至少一部分聚糖缺乏岩藻糖。 本发明还提供了构建体; 质粒; 矢量; 转化的植物愈伤组织，转化的植物组织（例如叶，种子，块茎等）和转化的用于产生这种免疫球蛋白的整个植物; 生产免疫球蛋白的方法; 通过公开的方法产生的免疫球蛋白; 以及使用这种免疫球蛋白。

公开(公告)号：WO1995018634A1

公开(公告)日：1995-07-13

申请号：PCT/US1995000067

申请日：1995-01-04

申请人： THE SCRIPPS RESEARCH INSTITUTE

发明人： THE SCRIPPS RESEARCH INSTITUTE ,  BURTON, Dennis, R. ,  WILLIAMSON, Robert, A. ,  BURIONI, Roberto ,  SANNA, Pietro, Paolo

IPC分类号： A61K39/395

CPC分类号： C07K16/4216 ,  A61K38/00 ,  A61K39/00 ,  C07K16/087 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

摘要： The present invention describes human monoclonal antibodies which immunoreact with Herpes simplex virus Type-1 and Type-2. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as nucleic acids and cell lines for producing the monoclonal antibodies.

摘要翻译： 本发明描述了与单纯疱疹病毒1型和2型免疫反应的人单克隆抗体。 还公开了使用单克隆抗体以及用于产生单克隆抗体的核酸和细胞系的免疫治疗和诊断方法。

公开(公告)号：WO1992021751A1

公开(公告)日：1992-12-10

申请号：PCT/NL1992000097

申请日：1992-06-05

申请人： STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT ,  RIJSEWIJK, Franciscus, Antonius, Maria ,  VAN OIRSCHOT, Johannes, Theodorus ,  MAES, Roger, Kamiel

发明人： STICHTING CENTRAAL DIERGENEESKUNDIG INSTITUUT

IPC分类号： C12N15/00

CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/265 ,  A61K2039/5254 ,  A61K2039/552 ,  C07K16/087 ,  C07K2319/00 ,  C12N15/86 ,  C12N2710/16722 ,  C12N2710/16732 ,  C12N2710/16734 ,  C12N2710/16743

摘要： Deletion mutant of bovine herpesvirus type 1 which has a deletion in the glycoprotein gE-gene. The mutant may further have a deletion in the thymidine kinase gene and/or the glycoprotein gI-gene, or have an insertion of a heterologous gene. Recombinant nucleic acid which comprises the gE-gene or a part thereof. Glycoprotein gE, peptides based thereon and complexes of the glycoproteins gE and gI, and antibodies against them. Vaccines and diagnostic kits comprising any one of these materials.

摘要翻译： 牛疱疹病毒1型的缺失突变体，其在糖蛋白gE基因中具有缺失。 突变体还可以在胸苷激酶基因和/或糖蛋白gI基因中具有缺失，或者具有异源基因的插入。 包含gE基因或其一部分的重组核酸。 糖蛋白gE，基于其的肽和糖蛋白gE和gI的复合物，以及针对它们的抗体。 包括任何一种这些材料的疫苗和诊断试剂盒。

公开(公告)号：WO1992001816A1

公开(公告)日：1992-02-06

申请号：PCT/US1991004907

申请日：1991-07-17

申请人： THE UNITED STATES OF AMERICA, as represented by ...

发明人： THE UNITED STATES OF AMERICA, as represented by ... ,  FRENKEL, Niza

IPC分类号： C12Q01/70

CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K16/087 ,  C12N7/00 ,  C12N2710/16522 ,  C12Q1/705 ,  G01N33/56994 ,  Y10S435/81

摘要： The present invention relates to a new human herpesvirus-7, proteins encoded in the genome of the virus, and antibodies specific for the virus and proteins. The virus was isolated from human peripheral blood mononuclear cells following incubation of the cells under conditions promoting T cell activation. Cultures of lymphocytes infected with the virus exhibited a cytopathic effect and electron microscopic analyses revealed a characteristic herpesvirus structure. The new virus is distinct from previously characterized human herpesvirus. The invention also relates to bioassays for the diagnosis of human herpesvirus-7 and the detection of human herpesvirus-7 in a biological sample. It further relates to a vaccine for humans against human herpesvirus-7.

公开(公告)号：WO1990007861A1

公开(公告)日：1990-07-26

申请号：PCT/US1989005857

申请日：1989-12-28

申请人： PROTEIN DESIGN LABS, INC.

发明人： PROTEIN DESIGN LABS, INC. ,  QUEEN, Cary, L. ,  SELICK, Harold, Edwin

IPC分类号： C12P21/00

CPC分类号： C07K16/087 ,  A61K38/00 ,  C07K16/00 ,  C07K16/088 ,  C07K16/249 ,  C07K16/2803 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/465 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/30

摘要： Novel methods for designing humanized immunoglobulins having one or more complementary determining regions (CDR's) from a donor immunoglobulin and a framework region from a human immunoglobulin comprising first comparing the framework or variable region amino acid sequence of the donor immunoglobulin to corresponding sequences in a collection of human immunoglobulin chains, and selecting as the human immunoglobulin one of the more homologous sequences from the collection. Each humanized immunoglobulin chain may comprise about 3 or more amino acids from the donor immunoglobulin in addition to the CDR's, usually at least one of which is immediately adjacent to a CDR in the donor immunoglobulin. The heavy and light chains may each be designed by using any one or all three additional position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

摘要翻译： 用于设计具有来自供体免疫球蛋白的一个或多个互补决定区（CDR）和来自人免疫球蛋白的框架区的人源化免疫球蛋白的新方法包括首先将供体免疫球蛋白的框架或可变区氨基酸序列与相应的序列集合 人免疫球蛋白链，并从该集合中选择作为人免疫球蛋白的更多同源序列之一。 除了CDR之外，每个人源化免疫球蛋白链可以包含来自供体免疫球蛋白的约3个或更多个氨基酸，通常其至少一个紧邻供体免疫球蛋白中的CDR。 重链和轻链可以通过使用任何一个或所有三个附加位置标准来设计。 当组合成完整的抗体时，本发明的人源化免疫球蛋白在人体中将基本上是非免疫原性的，并且保留与抗原例如含有表位的蛋白质或其它化合物基本上与供体免疫球蛋白相同的亲和力。

公开(公告)号：WO1990004176A1

公开(公告)日：1990-04-19

申请号：PCT/US1989004205

申请日：1989-09-28

申请人： SCRIPPS CLINIC AND RESEARCH FOUNDATION

发明人： SCRIPPS CLINIC AND RESEARCH FOUNDATION ,  NEMEROW, Glen, R. ,  COOPER, Neil, R.

IPC分类号： G01N33/53

CPC分类号： C07K19/00 ,  A61K38/00 ,  C07K14/005 ,  C07K14/705 ,  C07K16/087 ,  C12N2710/16222

摘要： CR2 reactive polypeptides that correspond to amino acid residues in the amino terminal region of EBVgp350/220 and analogues thereof are described. Polypeptide sequences that correspond to at least 5 contiguous residues of the linear sequence of EBVgp350/220 and include at least one of residues 21-24 or 25-27 of the linear sequence bind to the CR2 receptor. Polypeptide aggregates comprising at least two CR2 reactive polypeptides find use as immunopotentiators, stimulating B cells. The aggregates also inhibit infection of B cells by EBV. Treatment methods and diagnostics are also described.

摘要翻译： 描述了对应于EBVgp350 / 220的氨基末端区域中的氨基酸残基的CR2反应性多肽及其类似物。 对应于EBVgp350 / 220的线性序列的至少5个连续残基并且包括线性序列的残基21-24或25-27中的至少一个的多肽序列与CR2受体结合。 包含至少两个CR2反应性多肽的多肽聚集体用作免疫增强剂，刺激B细胞。 聚集体还通过EBV抑制B细胞的感染。 还描述了治疗方法和诊断。

公开(公告)号：WO2019027930A1

公开(公告)日：2019-02-07

申请号：PCT/US2018/044435

申请日：2018-07-30

申请人： RAIRIE, Raymond Joel

发明人： RAIRIE, Raymond Joel

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/245

CPC分类号： C07K16/087 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/525 ,  C12N2710/16634

摘要： The PINBALL HERPES ANTIBODY SYSTEM prevents people from getting HERPES. It prevents people from getting HERPES SIMPLEX 1 VIRUS (HSV-1) (HERPES 1) on their genitals, mouth, anus, hands, eyes and face. It also prevents people from getting SIMPLEX 2 VIRUS (HSV-2) (HERPES 2) on their genitals, mouth, anus, hands, eyes and face. And it prevents a baby from getting infected with HERPES 1 and HERPES 2 during birth.